Catalysts for Boehringer Ingelheim Corp
113 tracked
Jun 11, 2021
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Jun 11, 2021
approval
SYNJARDY XR (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + metformin hydrochloride ER)
โ
Jun 11, 2021
approval
SYNJARDY XR (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + metformin hydrochloride ER)
โ
Oct 30, 2020
approval
TRIJARDY XR (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
โ
Mar 30, 2020
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Jan 27, 2020
approval
TRIJARDY XR (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
โ
Jan 24, 2020
approval
JARDIANCE (EMPAGLIFLOZIN) โ FDA approval
SYNJARDY
โ
Jan 24, 2020
approval
SYNJARDY (EMPAGLIFLOZIN) โ FDA approval
SYNJARDY
โ
Jan 24, 2020
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Jan 24, 2020
approval
SYNJARDY XR (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + metformin hydrochloride ER)
โ
Sep 13, 2019
approval
CYLTEZO (ADALIMUMAB-ADBM) โ FDA approval
CYLTEZO
โ
Jul 3, 2019
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Jul 1, 2019
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Dec 21, 2018
approval
JARDIANCE (EMPAGLIFLOZIN) โ FDA approval
SYNJARDY
โ
Oct 26, 2018
approval
JARDIANCE (EMPAGLIFLOZIN) โ FDA approval
SYNJARDY
โ
Oct 26, 2018
approval
SYNJARDY (EMPAGLIFLOZIN) โ FDA approval
SYNJARDY
โ
Oct 26, 2018
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Oct 26, 2018
approval
SYNJARDY XR (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + metformin hydrochloride ER)
โ
Dec 13, 2017
approval
JARDIANCE (EMPAGLIFLOZIN) โ FDA approval
SYNJARDY
โ
Dec 13, 2017
approval
SYNJARDY (EMPAGLIFLOZIN) โ FDA approval
SYNJARDY
โ
Dec 13, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Dec 13, 2017
approval
SYNJARDY XR (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + metformin hydrochloride ER)
โ
Aug 25, 2017
approval
CYLTEZO (ADALIMUMAB-ADBM) โ FDA approval
CYLTEZO
โ
Aug 10, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Aug 10, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Mar 14, 2017
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Dec 23, 2016
approval
SYNJARDY (EMPAGLIFLOZIN) โ FDA approval
SYNJARDY
โ
Dec 23, 2016
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Dec 23, 2016
approval
GLYXAMBI (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + linagliptin)
โ
Dec 23, 2016
approval
SYNJARDY XR (EMPAGLIFLOZIN) โ FDA approval
(empagliflozin + metformin hydrochloride ER)
โ